Literature DB >> 23015280

Comparison of initial warfarin response in obese patients versus non-obese patients.

Jessica L Wallace1, Anne B Reaves, Elizabeth A Tolley, Carrie S Oliphant, Lydia Hutchison, Numan Abdulraman Alabdan, Christopher W Sands, Timothy H Self.   

Abstract

Achieving therapeutic anticoagulation with warfarin is complicated by substantial inter-patient and intra-patient variability with numerous factors known to influence dose requirements. Obesity is one factor for which there remains no study to date investigating its initial effect on warfarin response assessed by INR, stratified by BMI category in hospitalized patients. To compare initial warfarin response between obese and non-obese patients by evaluating average daily dose (ADD), time required to attain therapeutic INR, and mean discharge dose (MDD), stratified by BMI category. A retrospective review was conducted to evaluate initial warfarin response in hospitalized patients of different BMI categories initiated on warfarin with ≥4 consecutive days of therapy and managed by pharmacy dosing service. 211 patients were included (10 underweight, 45 normal weight, 48 overweight, 71 obese, 37 morbidly obese). Across BMI categories, the percentage of patients attaining therapeutic INR prior to discharge differed (p = 0.0004) with 71.1 % of normal weight therapeutic compared to 42.3 % of obese and 38 % of morbidly obese. Within BMI categories, when comparing ADD between patients therapeutic and subtherapeutic at discharge, no differences were observed, except among overweight patients (5.6 ± 0.3 vs. 7 ± 0.4 mg, p = 0.0143). Compared to normal weight, obese and morbidly obese required a significantly longer median time to achieve therapeutic INR (8 and 10 days vs. 6 days) and a higher ADD (6.6 ± 0.3 and 7.6 ± 0.5 vs. 5 ± 0.3 mg) and MDD (6.7 ± 0.5 and 6.7 ± 0.7 vs. 4.4 ± 0.5 mg). Compared to normal weight, obese and morbidly obese patients had a decreased initial response to warfarin.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23015280     DOI: 10.1007/s11239-012-0811-x

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  14 in total

Review 1.  Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health.

Authors: 
Journal:  Obes Res       Date:  1998-09

2.  Control of warfarin therapy in the elderly.

Authors:  J T Eccles
Journal:  Age Ageing       Date:  1975-08       Impact factor: 10.668

3.  Obesity is associated with a slower response to initial phenprocoumon therapy whereas CYP2C9 genotypes are not.

Authors:  Cordula Meyer zu Schwabedissen; Vera Mevissen; Fabian Schmitz; Seth Woodruff; Georg Langebartels; Thomas Rau; Klaus Zerres; Rainer Hoffmann; Jan R Ortlepp
Journal:  Eur J Clin Pharmacol       Date:  2006-07-18       Impact factor: 2.953

4.  Factors affecting warfarin requirements. A prospective population study.

Authors:  P A Routledge; P H Chapman; D M Davies; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1979-06-12       Impact factor: 2.953

5.  Overweight, obesity, and the risk of recurrent venous thromboembolism.

Authors:  Sabine Eichinger; Gregor Hron; Christine Bialonczyk; Mirko Hirschl; Erich Minar; Oswald Wagner; Georg Heinze; Paul A Kyrle
Journal:  Arch Intern Med       Date:  2008-08-11

6.  Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.

Authors:  Farhad Kamali; Tayyaba Irfan Khan; Barry P King; Richard Frearson; Patrick Kesteven; Peter Wood; Ann K Daly; Hilary Wynne
Journal:  Clin Pharmacol Ther       Date:  2004-03       Impact factor: 6.875

7.  The initial phase of oral anticoagulation with warfarin in outpatients with deep venous thrombosis.

Authors:  Walter Ageno; Luigi Steidl; Carolina Ultori; Francesco Dentali; Chiara Marchesi; Valentina Mera; Alessandro Squizzato; Achille Venco
Journal:  Blood Coagul Fibrinolysis       Date:  2003-01       Impact factor: 1.276

Review 8.  Frequency of adverse events in patients with poor anticoagulation: a meta-analysis.

Authors:  Natalie Oake; Dean A Fergusson; Alan J Forster; Carl van Walraven
Journal:  CMAJ       Date:  2007-05-22       Impact factor: 8.262

9.  Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.

Authors:  Brian F Gage; Charles Eby; Paul E Milligan; Gerald A Banet; Jill R Duncan; Howard L McLeod
Journal:  Thromb Haemost       Date:  2004-01       Impact factor: 5.249

10.  Genetic determinants of response to warfarin during initial anticoagulation.

Authors:  Ute I Schwarz; Marylyn D Ritchie; Yuki Bradford; Chun Li; Scott M Dudek; Amy Frye-Anderson; Richard B Kim; Dan M Roden; C Michael Stein
Journal:  N Engl J Med       Date:  2008-03-06       Impact factor: 91.245

View more
  11 in total

1.  Evaluation of the impact of body mass index on warfarin requirements in hospitalized patients.

Authors:  Katie B Tellor; Steffany N Nguyen; Amanda C Bultas; Anastasia L Armbruster; Nicholas A Greenwald; Abigail M Yancey
Journal:  Ther Adv Cardiovasc Dis       Date:  2018-06-19

2.  Body mass index predicts major bleeding risks in patients on warfarin.

Authors:  Adedotun A Ogunsua; Sunkaru Touray; Justin K Lui; Tiffany Ip; Jorge V Escobar; Joel Gore
Journal:  J Thromb Thrombolysis       Date:  2015-11       Impact factor: 2.300

3.  Analysis of the first therapeutic-target-achieving time of warfarin therapy and associated factors in patients with pulmonary embolism.

Authors:  Xiaowei Gong; Haiyan Wang; Yadong Yuan
Journal:  Exp Ther Med       Date:  2016-08-23       Impact factor: 2.447

Review 4.  Mechanisms of thrombosis in obesity.

Authors:  Ilya O Blokhin; Steven R Lentz
Journal:  Curr Opin Hematol       Date:  2013-09       Impact factor: 3.284

5.  Pharmacoepidemiologic study of warfarin prescription in a Brazilian tertiary hospital.

Authors:  Camilo Molino Guidoni; Paulo Roque Obreli-Neto; Leonardo Regis Leira Pereira
Journal:  J Thromb Thrombolysis       Date:  2014-05       Impact factor: 2.300

Review 6.  Oral drug dosing following bariatric surgery: General concepts and specific dosing advice.

Authors:  Jurjen S Kingma; Desirée M T Burgers; Valerie M Monpellier; Marinus J Wiezer; Heleen J Blussé van Oud-Alblas; Janelle D Vaughns; Catherine M T Sherwin; Catherijne A J Knibbe
Journal:  Br J Clin Pharmacol       Date:  2021-06-03       Impact factor: 3.716

Review 7.  Use of novel oral anticoagulants for the treatment of venous thromboembolism and its considerations in Asian patients.

Authors:  Yun-Jeong Lee
Journal:  Ther Clin Risk Manag       Date:  2014-10-07       Impact factor: 2.423

8.  Correlation between Rs2108622 Locus of CYP4F2 Gene Single Nucleotide Polymorphism and Warfarin Dosage in Iranian Cardiovascular Patients.

Authors:  Shahdah Khosropanah; Seyed Nooreddin Faraji; Hamzeh Habibi; Majid Yavarian; Roohollah Mansoori; Sezaneh Haghpanah
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

9.  Nutritional management of a patient with obesity and pulmonary embolism: a case report.

Authors:  Maria Luisa Fonte; Lauren Fietchner; Matteo Manuelli; Hellas Cena
Journal:  Nutr J       Date:  2016-10-19       Impact factor: 3.271

10.  Rivaroxaban Versus Warfarin for Management of Obese African Americans With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis.

Authors:  Olivia S Costa; Jan Beyer-Westendorf; Veronica Ashton; Dejan Milentijevic; Kenneth Todd Moore; Thomas J Bunz; Craig I Coleman
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.